Skip to main content

What the FDA labels say about taking them together

Atazanavir/cobicistat and maraviroc

Atazanavir/cobicistat's FDA label of May 12, 2025 names maraviroc in its drug interactions section; the maraviroc label PlainMeds reads does not name atazanavir/cobicistat.

Check it at the source: the atazanavir/cobicistat FDA label on DailyMed (effective May 12, 2025, E.R. Squibb & Sons, L.L.C.); the maraviroc FDA label on DailyMed (effective September 26, 2022, ViiV Healthcare Company).

What does the atazanavir/cobicistat label say about maraviroc?

Atazanavir/cobicistat label, drug interactions

Concomitant Drug Class/Specific Drugs: maraviroc; Effect b on Concentration: ↑ maraviroc; Clinical Comment: When coadministering maraviroc and EVOTAZ, patients should receive maraviroc 150 mg twice daily.

Source: FDA drug label (EVOTAZ), NDA206353 (Bristol), as published by E.R. Squibb & Sons, L.L.C., effective May 12, 2025 (SPL set 83db29d7-5d85-49d6-8cb6-740473365cf8), via openFDA; the full label on DailyMed

What does the maraviroc label say about atazanavir/cobicistat?

Maraviroc's label (effective September 26, 2022) does not name atazanavir/cobicistat in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (SELZENTRY), ViiV Healthcare Company, effective September 26, 2022 (SPL set 46f30ac5-c96b-429e-976d-8c5ee1c0761b), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Atazanavir/cobicistat generic labelers
8Maraviroc generic labelers
Atazanavir/cobicistatMaraviroc
Labeled forHIVHIV
Boxed warningNoYes
Pharmacy cost (NADAC)$52.05 per tablet 300 mg-150 mg tablet$9.15 per tablet 150 mg tablet
Shortage nowA presentation being discontinuedA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?